Trials / Completed
CompletedNCT00156078
A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)
A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 450 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin |
Timeline
- Start date
- 2005-01-01
- Completion
- 2007-05-01
- First posted
- 2005-09-12
- Last updated
- 2021-01-25
Locations
35 sites across 19 countries: Argentina, Brazil, Chile, Colombia, Ecuador, Indonesia, Jordan, Lebanon, Malaysia, Mexico, Philippines, Saudi Arabia, Singapore, South Korea, Taiwan, Thailand, Turkey (Türkiye), United Arab Emirates, Venezuela
Source: ClinicalTrials.gov record NCT00156078. Inclusion in this directory is not an endorsement.